Melbourne has emerged as a powerhouse for biotechnology and pharmaceutical manufacturing in the Southern Hemisphere. As the capital of Victoria, Melbourne hosts a world-class biomedical precinct that rivals those in Boston and London. The city is home to prestigious research institutions like the Peter Doherty Institute for Infection and Immunity and the Monash Institute of Pharmaceutical Sciences, which drive innovation in antibiotic drug development.
Antibiotic drug factories in Melbourne operate under the rigorous standards of the Therapeutic Goods Administration (TGA), ensuring that every vial and tablet produced meets international GMP (Good Manufacturing Practice) requirements. The local industrial ecosystem is characterized by a mix of established global giants and agile, high-tech exporters that specialize in veterinary and human pharmaceutical ingredients.
Leveraging AI-driven drug discovery to combat antimicrobial resistance (AMR) within the Melbourne Research Corridor.
Strategic export routes via the Port of Melbourne, connecting pharmaceutical supplies to Asia-Pacific and beyond.
Stringent TGA and GMP compliance frameworks ensuring premium safety profiles for all antibiotic drugs.
The antibiotic industry in Melbourne is currently undergoing a digital transformation. Factories are integrating Artificial Intelligence (AI) and Machine Learning to optimize batch processing and predict molecular stability. This "Industry 4.0" approach allows exporters to maintain competitive pricing while increasing the purity of active pharmaceutical ingredients (APIs) such as Tylosin and Florfenicol.
Sustainability is another key driver. Melbourne-based manufacturers are pioneering "Green Chemistry" to reduce the environmental footprint of pharmaceutical production. This includes recycling solvents and implementing high-efficiency filtration systems to protect the local Victorian ecosystem.
In the vast pastoral lands of Victoria and surrounding states, Melbourne-produced antibiotic drugs play a critical role in livestock health. Veterinary antibiotics are essential for maintaining the productivity of Australia's multi-billion dollar cattle, sheep, and poultry industries.
Our facilities are equipped with the latest technology to assemble and produce larger quantities of intermediates. We provide advanced manufacturing capabilities, including:
For our main product intermediates, we maximize our technological advantages to complete complex tasks within specified global deadlines.
Located in the heart of the tech-hub, Hangzhou Jeci Biochem Technology Co., Ltd. is a leading force in the pharmaceutical sector. We are committed to the sales of active pharmaceutical ingredients (APIs), nutritional products, and food additives. Our core strengths lie in cooperative R&D, custom manufacturing, and global service excellence.
In China, we have a strong collaborative R&D team working in depth with new drug research institutes. We manage extensive domestic sales channels and maintain long-term relationships for product applications, technology transfer, and exclusive agency services. Furthermore, we provide consulting for factory quality management system certifications.
Internationally, our reach extends to Melbourne, India, Southeast Asia, South Korea, and Japan. We provide comprehensive market and sales services, including product registration and channel expansion for overseas companies looking to enter the Chinese market.
High-grade intermediates for life-saving drugs.
Essential materials for chemical processing.
Building blocks for complex chemical structures.
SJ medical
